Step 1 topics → Hematology and Oncology → Acute Myeloid Leukemia (AML) and APL

Acute Myeloid Leukemia (AML) and APL

USMLE Step 1 trap: Confuses TLS with DIC as the dominant early complication of cytotoxic chemo in APL. Standard cytotoxic chemo lyses APL blasts and releases their azurophilic granules, triggering catastrophic disseminated intravascular coagulation (DIC), not TLS.

Acute myeloid leukemia is a clonal expansion of myeloid precursors that fail to mature, and USMLE Step 1 loves testing it from multiple angles: morphology (Auer rods, MPO positivity), cytogenetics (especially the APL translocation), and clinical management. The most dangerous wrong answer: starting standard cytotoxic chemotherapy in APL. APL blasts are packed with procoagulant granules; lysing them with standard chemo causes catastrophic DIC, not tumor lysis syndrome. ATRA differentiates the blasts instead of rupturing them, avoiding this complication entirely. The highest-yield subtype is APL (FAB M3), and nailing its mechanism, complication, and targeted therapy covers the majority of AML points on the exam.

The tricky part is that AML shares surface with other leukemias, and the exam exploits that. Students mix up translocations across leukemia types, confuse what MPO staining means, and misunderstand how ATRA works. The biggest trap is thinking about APL the same way you think about other AML subtypes — it isn't. Standard cytotoxic chemotherapy in APL doesn't just cause tumor lysis syndrome like in other cancers; it causes catastrophic DIC by dumping azurophilic granules from lysed blasts. That distinction is clinically and exam-critical.

USMLE Step 1 will give you a patient with a bleeding disorder and leukemia, or a lab result showing Auer rods, and ask you to connect those findings to the right diagnosis, complication, or treatment. Understanding the mechanism — not just memorizing facts — is what separates a correct answer from a trap.

From real student decks
73%have cards covering this topic
51%have mature cards
1median lapses in 14 days

Common misconceptions

Common mistake
Wrong: Standard cytotoxic chemotherapy in APL causes tumor lysis syndrome (TLS) as the primary life-threatening complication.
Right: Standard cytotoxic chemo lyses APL blasts and releases their azurophilic granules, triggering catastrophic disseminated intravascular coagulation (DIC), not TLS.
Tumor lysis syndrome results from rapid cell death releasing intracellular contents (uric acid, potassium, phosphate) and is a concern with many leukemia treatments — but it is NOT the dominant early killer in APL. APL blasts are packed with azurophilic granules that contain procoagulant material; when cytotoxic chemo lyses these cells en masse, those granules spill out and activate the coagulation cascade, causing disseminated intravascular coagulation. This is why APL carries a high early mortality with standard chemo, and why ATRA — which differentiates blasts rather than lysing them — was such a breakthrough.
Common mistake
Wrong: ATRA kills APL blasts directly like conventional chemotherapy.
Right: ATRA induces terminal differentiation of APL blasts into mature granulocytes, avoiding granule dump and preventing DIC.
ATRA (all-trans retinoic acid) does not kill APL blasts the way cytotoxic agents do. Instead, it binds the aberrant PML-RARA fusion protein and forces terminal differentiation of the arrested promyelocytes into mature neutrophils. Because the cells mature rather than rupture, the granules are released in a controlled physiologic manner and catastrophic DIC is avoided. This is a classic example of differentiation therapy and a conceptual model the exam expects you to apply — not just memorize.
Common mistake
Wrong: Myeloperoxidase (MPO) positivity on cytochemistry can be seen in ALL as well as AML.
Right: MPO positivity (Auer rods, Sudan black B staining) is specific to myeloid lineage and distinguishes AML from ALL.
Myeloperoxidase is an enzyme found in the azurophilic granules of myeloid cells — it is a marker of myeloid lineage, period. MPO positivity on cytochemistry (or Auer rods, which are crystallized MPO) tells you the blast is of myeloid origin and rules out ALL, which is lymphoid. ALL blasts are MPO-negative and instead stain with TdT and surface markers like CD19 (B-cell) or CD3 (T-cell). Don't let the exam blur this line — MPO is myeloid-specific.
Common mistake
Wrong: The t(9;22) Philadelphia chromosome is the defining translocation of APL.
Right: APL is defined by t(15;17), which fuses PML to RARA and is the target of ATRA therapy; t(9;22) defines CML.
t(9;22) — the Philadelphia chromosome — fuses BCR to ABL and defines CML (and a subset of ALL), not APL. APL is defined by t(15;17), which places the PML gene next to RARA, producing a fusion protein that blocks myeloid differentiation at the promyelocyte stage. This distinction matters clinically: ATRA works precisely because it overcomes the differentiation block caused by PML-RARA. On USMLE Step 1, if you see a leukemia question with t(9;22), think CML; if you see t(15;17) with DIC and Auer rods, think APL.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Given a CBC, bone marrow biopsy description, or cytochemistry result, identify the morphologic and immunophenotypic features (Auer rods, MPO positivity, Sudan black B staining) that distinguish AML from ALL and other leukemias.
  2. Given a patient with APL (FAB M3), identify the defining translocation t(15;17) and its molecular product PML-RARA, explain why standard cytotoxic chemotherapy causes DIC (not TLS), and select the correct differentiation therapy (ATRA ± arsenic trioxide).
  3. Given a clinical history (prior chemotherapy exposure, radiation, Down syndrome, benzene exposure, prior myelodysplastic syndrome), identify the predisposing risk factors that increase AML risk and distinguish them from risk factors for other hematologic malignancies.

Can you avoid these mistakes?

A 35-year-old woman presents with gum bleeding and petechiae. CBC shows WBC 40,000 with predominant blasts. Bone marrow biopsy shows cells with abundant azurophilic granules and Auer rods. Cytochemistry is MPO-positive. What is the translocation, and what is the most dangerous early complication if you treat her with standard cytotoxic chemotherapy?
A first-year intern wants to start standard induction chemotherapy (7+3) for a newly diagnosed APL patient. You stop them. Explain mechanistically why this is dangerous and what the correct first-line therapy is instead.
A patient has a leukemia with blasts that are MPO-negative, TdT-positive, and CD19-positive. Does this support AML or ALL? Would you expect Auer rods on peripheral smear?
A 58-year-old man with a history of prior treatment for breast cancer with alkylating agents now presents with fatigue and a new AML diagnosis. What class of risk factor does his prior treatment represent, and what other exposures or conditions carry similar AML risk?

Related topics

Leukemia vs Lymphoma Framework Hematopoiesis and Lineage Differentiation RBC Physiology and Lifespan WBC Differential and Function Platelet Physiology and Primary Hemostasis

See how your Anki deck covers this topic.

Upload your deck for a free audit →